Diuretics in the treatment of arterial hypertension: the role of torasemide

Cover Page

Cite item

Full Text

Abstract

Diuretics are widely used in clinical practice in the treatment of arterial hypertension. The thiazide (thiazide-type) and loop diuretics are widely used in general clinical practice. The article deals with the questions of rational choice of diuretics, using the available evidence-based data, the results of drug interaction and the monitoring of efficacy and safety of the therapy. The special attention is paid to torasemide - loop diuretic, which is recommended for long-term pharmacotherapy of arterial hypertension.

About the authors

T. E Morozova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: temorozova@gmail.com
д-р мед. наук, проф., зав. каф. клинической фармакологии и фармакотерапии ИПО ГБОУ ВПО Первый МГМУ им И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

I. Yu Yudina

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, ассистент каф. ГБОУ ВПО Первый МГМУ им И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.
  2. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос. кардиол. журн. 2014; 1 (105): 7-94.
  3. Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAM 2014; 311 (5): 507-20. doi: 10.1001/Jama.2013.284427.
  4. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59-66; http://dx.doi.org/10.15829/1560-4071-2015-1-59-66
  5. Juaquerto D.C, Schini V.B, Vanhoutte .PM. Indapamide potentiates the endothelium - depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204-9.
  6. Gosse Ph, Sheridan D, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE Study. J Hypertension 2000; 18: 1465-75.
  7. Marre M, Garcia-Puig J, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertension 2004; 22: 1613-22.
  8. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358.
  9. Weidmann P. Metabolic profile of indapamide sustained - release in patients with hypertension. Drug Safety 2001; 24: 1155-65.
  10. Kostis J.B, Wilson A.C, Fruedenberger R.S. Long term effect of diuretic based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.
  11. Marre M, Garcia-Puig J, Kokot F et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertension 2007; 20: 90-7.
  12. Weidmann P. Metabolic profile of indapamide sustained - release in patients with hypertension. Drugs Safety 2001; 24: 1155-65.
  13. Hypertension Detection and Follow - up Program Cooperative Group. JAMA 1979; 242: 2562-71.
  14. Multiple Risk Factor Intervention Trial Research Group. Circulation. 1990; 82: 1616-28.
  15. SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.
  16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97.
  17. Carter B et al. Hypertension 2004; 43: 4-9.
  18. Calhoun D et al. Circulation 2008; 117: e510-e526.
  19. Bakris G et al. J Clin Hypertens (Greenwich) 2008; 10: 707-13.
  20. NICE clinical guideline. Clinical management of primary hypertension in adults. 2011. http://www.nice.org.uk/guidance/cg127/chapter/1-guidance
  21. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double - blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-9.
  22. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358.
  23. Морозова Т.Е. Артериальная гипертония у пожилых: особенности течения и выбор терапии. Consilium Medicum. 2012; 14 (5): 12-6.
  24. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-847.
  25. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7.
  26. De la Sierra A, Segura J, Banegas J.R et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898-902.
  27. Taler S.J, Textor S.C, Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982-8.
  28. Brater D.C, Leinfelder J, Anderson S.A. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187-92.
  29. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 4; 219 (3): 385-94.
  30. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188-90.
  31. Yamanaga K, Uchida T, Kido H et al. But not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64-5.
  32. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. Рос. мед. журн. 2014; 23: 1676-80.
  33. Жиров И.В. Место петлевых диуретиков в современных стандартах лечения ХСН. РМЖ. 2012; 25: 1298-304.
  34. Cosin J, Diez J. TORIC investigators. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail 2002; 4: 507-13.
  35. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV - Efficacy and quality of life. Eur J Heart Fail 2003; 5: 793-801.
  36. Lopez B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 2; 43 (11): 2028-35.
  37. TORAFIC Investigators Group. Effects of prolonged - release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded - end point, active - controlled study. Clin Ther 2011; 33 (9): 1204-13.
  38. Жиров И.В., Горюнова Т.В., Осмоловская Ю.Ф., Терещенко С.Н. Торасемид пролонгированного высвобождения у пациентов с хронической сердечной недостаточностью. Эффективная фармакотерапия. Кардиология и ангиология. 2014; 3 (25): 18-24.
  39. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80-91.
  40. Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. Может ли торасемид пролонгированного действия стать альтернативой тиазидным диуретикам при артериальной гипертонии? Мнение эксперта. Рос. мед. журн. 2012; 20: 1038-43.
  41. Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013; 2: 9-13.
  42. Achhammer I, Eberhard R. Comparison of serum potassium levels during long - term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmaco. Clin Pharmacol 1990; 8: 211-20.
  43. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63-8.
  44. Coca A. Long - term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
  45. Агеев Ф.Т., Жубрина Е.С., Середенина Е.М. и др. Сравнительная эффективность и безопасность длительного применения торасемида и фуросемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Сердечная недостаточность. 2013; 14 (2): 55-62.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies